aTyr Pharma, a San Diego-based biotherapeutics company addressing rare diseases, has appointed Sanjay Shukla as Chief Medical Officer. Shukla will lead aTyr’s clinical efforts to advance its Physiocrine biology therapeutic intervention points and develop medicines that promote tissue homeostasis for patients with rare diseases.
According to an official statement, Shukla worked as an external advisor on data analysis of aTyr Pharma’s Resolaris™ adult FSHD clinical study over the last few months. “Shukla ‘s deep experience with clinical development, data analysis and statistics, along with his background in both biotech and big pharma led clinical trials, across multiple therapeutic areas, including rare disease, provides us with a unique set of skills that complement our talented clinical development and operations teams,” stated aTyr Pharma CEO John Mendlein.
Shukla joined from Novartis as Vice President and Global Head of Integrated Medical Services, where he led global medical affairs operations, with oversight for all pharma general medicines therapies, both inline and in development. Previously, he was CEO of RxMd, a clinical development consultancy that assisted in advancing proof of concept for early stage drug candidates. Prior to that, he served in a variety of clinical development, data analytics and drug safety roles at Vifor Pharma and Aspreva Pharmaceuticals.
aTyr Pharma’s lead candidate, Resolaris™, is an intravenous protein therapeutic for the treatment of rare myopathies with an immune component. Resolaris is currently in a Phase 1b/2 clinical trial in adult patients with facioscapulohumeral muscular dystrophy (FSHD); a Phase 1b/2 trial in adult patients with limb girdle muscular dystrophy 2B (LGMD2B or dysferlinopathies) or FSHD; and a Phase 1b/2 trial in patients with an early onset form of FSHD.
Research and development expenses of aTyr Pharma for the year ended December 31, 2015 and 2014 were $34.5 million and $16.8 million, respectively.